التفاصيل البيبلوغرافية
| العنوان: |
Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case–control analysis. |
| المؤلفون: |
Wilson, Jessica C., Sarsour, Khaled, Collinson, Neil, Tuckwell, Katie, Musselman, David, Klearman, Micki, Napalkov, Pavel, Jick, Susan S., Stone, John H., Meier, Christoph R. |
| المصدر: |
Seminars in Arthritis & Rheumatism; Jun2017, Vol. 46 Issue 6, p819-827, 9p |
| مستخلص: |
Objective Giant cell arteritis (GCA) is an inflammatory vasculitis preferentially affecting large and medium-sized arteries. High-dose oral glucocorticoids (GCs) are the mainstay of GCA therapy. Using data from the UK Clinical Practice Research Datalink (CPRD), we examined the risk of oral GC-related serious adverse events (SAEs) in a UK population of patients with giant cell arteritis (GCA). Methods We conducted a series of nested case–control analyses in GCA patients to examine the effect of increasing dose of prednisolone on the risk of developing diabetes, glaucoma, osteoporosis, fractures, serious infection requiring hospitalization, and death. We used conditional logistic regression to calculate the unadjusted and multivariate odds ratios (ORs) with 95% CIs for the associations between prednisolone use and the risks of all outcomes of interest. We stratified the analyses by increasing cumulative prednisolone use and average daily dose. Results In the multivariate analyses, we observed a trend of increasing risk of diabetes and osteoporosis with increasing cumulative dose of oral prednisolone ( p trend < 0.05). GCA patients in the highest daily dose category (30 mg/d) had an increased risk of diabetes (adjusted OR, 95% CI) (4.7, 2.8–7.8), osteoporosis (1.9, 1.2–2.9), fractures (2.6, 1.6–4.3), glaucoma (3.5, 2.0–6.1), serious infection (3.3, 2.2–5.2), and death (2.1, 1.3–3.5) compared to those with lower average daily prednisolone doses (5 mg/d). Conclusion Compared to lower average daily prednisolone doses, high average daily doses were associated with an increased risk of serious adverse effects. [ABSTRACT FROM AUTHOR] |
|
Copyright of Seminars in Arthritis & Rheumatism is the property of W B Saunders and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
